Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenzumestrocel in Amyotrophic Lateral Sclerosis
NCT04745299Phase 3Completed
- Sponsor
- Corestemchemon
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 3 trial of lenzumestrocel in amyotrophic lateral sclerosis (ALS), sponsored by Corestemchemon. Started Feb 2021; status: completed.
02
Drugs
lenzumestrocel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04745299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745299.